123 related articles for article (PubMed ID: 30220971)
1. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Nuryadi E; Sasaki Y; Hagiwara Y; Permata TBM; Sato H; Komatsu S; Yoshimoto Y; Murata K; Ando K; Kubo N; Okonogi N; Takakusagi Y; Adachi A; Iwanaga M; Tsuchida K; Tamaki T; Noda SE; Hirota Y; Shibata A; Ohno T; Tokino T; Oike T; Nakano T
Oncotarget; 2018 Aug; 9(66):32642-32652. PubMed ID: 30220971
[TBL] [Abstract][Full Text] [Related]
2. Mutation Analysis of Radioresistant Early-Stage Cervical Cancer.
Oike T; Sekiguchi Y; Yoshimoto Y; Oike T; Ando K; Gu W; Sasaki Y; Tokino T; Iwase A; Ohno T
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008475
[TBL] [Abstract][Full Text] [Related]
3. Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer.
Hu B; Ma X; Huang R; Wu Z; Lu J; Guo Y; Tang J; Ma C; Ma J; Zhang L; Bai Y
Front Oncol; 2021; 11():697308. PubMed ID: 34434896
[TBL] [Abstract][Full Text] [Related]
4. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.
Frumovitz M; Burzawa JK; Byers LA; Lyons YA; Ramalingam P; Coleman RL; Brown J
Gynecol Oncol; 2016 Jun; 141(3):588-591. PubMed ID: 27079212
[TBL] [Abstract][Full Text] [Related]
6. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
7. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
8. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
11. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
13. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-125 modulates radioresistance through targeting p21 in cervical cancer.
Pedroza-Torres A; Campos-Parra AD; Millan-Catalan O; Loissell-Baltazar YA; Zamudio-Meza H; Cantú de León D; Montalvo-Esquivel G; Isla-Ortiz D; Herrera LA; Ángeles-Zaragoza Ó; Robelo-Romero G; Herrera-Gómez Á; Pérez-Plasencia C
Oncol Rep; 2018 Mar; 39(3):1532-1540. PubMed ID: 29399698
[TBL] [Abstract][Full Text] [Related]
15.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
16. Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB; Belchis D; Tseng LH; Nguyen D; De Marchi F; Haley L; Riel S; Beierl K; Zheng G; Brahmer JR; Askin FB; Gocke CD; Eshleman JR; Forde PM; Lin MT
Oncotarget; 2017 Nov; 8(57):96684-96696. PubMed ID: 29228562
[TBL] [Abstract][Full Text] [Related]
17. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
19. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.
Grünewald I; Vollbrecht C; Meinrath J; Meyer MF; Heukamp LC; Drebber U; Quaas A; Beutner D; Hüttenbrink KB; Wardelmann E; Hartmann W; Büttner R; Odenthal M; Stenner M
Oncotarget; 2015 Jul; 6(20):18224-37. PubMed ID: 26053092
[TBL] [Abstract][Full Text] [Related]
20. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
